Inavir cleared for flu prevention in Japan
This article was originally published in Scrip
Daiichi Sankyo's long-acting neuraminidase inhibitor Inavir (laninamivir octanoate) has been approved in Japan for the additional indication of prophylaxis of influenza types A and B.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.